SMAD2 and central nervous system cancer: For example, TGF-β-treated U87 and U251 glioma cells undergo mesenchymal-like transformation through the induction of the Smad2 signaling pathway, leading to morphological changes, up-regulation of mesenchymal markers, and increased glioma cell invasion and migration [12, 13].